1	Title
2	Estimated Incidence of Respiratory Hospitalizations Attributable to RSV Infections
3	across Age and Socioeconomic Groups
4	Authors
5	Zhe Zheng ¹ *, Joshua L. Warren ² , Eugene D. Shapiro, ³
6	Virginia E. Pitzer ¹ , Daniel M. Weinberger ¹
7	
8	Affiliations
9	¹ Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale
10	School of Public Health, New Haven, CT, USA.
11	² Department of Biostatistics and the Public Health Modeling Unit, Yale School of Public Health,
12	New Haven, CT, USA.
13	³ Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA
14	
15	* Corresponding Author:
16	Zhe Zheng,
17	Department of Epidemiology of Microbial Diseases,
18	Yale University,
19	60 College Street, New Haven, Connecticut, USA
20	<u>zhe.zheng@yale.edu</u> ,
21	Tel: +1(203)-298-2435

22 Abstract: [word count: 238 words]

23 Background:

24 Surveillance for respiratory syncytial virus (RSV) likely captures just a fraction of the burden of

25 disease. Understanding the burden of hospitalizations and disparities between populations can

26 help to inform upcoming RSV vaccine programs and to improve surveillance.

27 Methods:

We obtained monthly age-, ZIP code- and cause-specific hospitalizations in New York, New Jersey, and Washington from the US State Inpatient Databases (2005-2014). We estimated the incidence of respiratory hospitalizations attributable to RSV by age and by socioeconomic status using regression models. We compared the estimated incidence and the recorded incidence (based on ICD9-CM) of RSV hospitalizations to estimate the under-recorded rate in the different

33 sub-populations.

34 Results:

The estimated annual incidence of respiratory hospitalizations due to RSV was highest among infants <1 year of age with low socioeconomic status, (2700 per 100,000 people, 95% CrI [2600, 2900]) and were considerable in older adults that are ≥65 years of age across socioeconomic status, ranging from 130 to 970 per 100,000 people. The incidence of hospitalization recorded as being due to RSV represented a significant undercount, particularly in adults. Only <5% of the estimated RSV hospitalizations were captured for the older adults that are ≥65 years of age.

41 Conclusions:

RSV causes a considerable burden of hospitalization in young children and in older adults in the
U.S, with variation by socioeconomic group. Estimates of the incidence of hospitalizations due
to RSV in older adults based on the recorded diagnoses likely represent an underestimate.

46 Key messages

47 What is already known on this topic?

48 Previous study suggested that the incidence of hospitalization for bronchiolitis (often caused by

49 RSV) in infants varies greatly between communities of different socioeconomic levels. However,

50 it is unclear whether these differences are associated with the admission criteria or the risk of

51 RSV infection.

52 What this study adds?

53 The estimated annual incidence of respiratory hospitalizations due to RSV in infants residing in

54 low socioeconomic areas was about twice as high as the incidence in infants residing in high

socioeconomic areas. In older adults, a small fraction of the hospitalizations estimated to be

caused by RSV were recorded as such in the inpatient database.

57 How this study might affect research, practice or policy?

58 With several vaccines and extended half-life monoclonal antibodies against RSV under active

59 development, these estimates can help anticipate the impact of RSV prevention strategies in

60 populations of different demographic characteristics.

61 Introduction

Respiratory syncytial virus (RSV) causes a large burden of disease in infants, young children, and the elderly ¹². Although no vaccine against RSV is currently available, multiple vaccines and extended-duration prophylaxis are in development, and preliminary estimates of their efficacy are promising ³⁴. To accurately assess the potential impact of interventions against RSV, it is essential to evaluate the health burden of RSV in sub-populations with different demographic and socioeconomic characteristics.

Though the epidemic dynamics of RSV vary even within local geographic areas ⁵⁶, little is known about how the burden of RSV varies between populations. Previous research has had mixed conclusions about the impact of socioeconomic status (SES) on the risk of RSV infections ⁷⁻⁹. While some of the studies found lower rates of RSV infection in higher SES groups, others found no relationship. The incidence of hospitalization for bronchiolitis in infants (often caused by RSV) varies greatly between communities of different socioeconomic levels ¹⁰⁻¹².

Rates of hospitalizations recorded as being due to RSV infections can also be influenced by testing and coding practices. RSV-associated hospitalizations are likely under-ascertained using laboratory surveillance data. The decision to conduct a diagnostic test for RSV infection and the sensitivity of the tests can influence the completeness of detection. For instance, compared with children, adults are less likely to be tested for RSV, and the diagnostic tests have lower sensitivity in adults ^{13 14}.

80 The goal of this study was to quantify the annual incidence of hospitalizations associated with
81 RSV in different localities and to estimate the degree of under-recording between sub-

populations in different localities. To achieve this, we fitted regression models to time series data
from comprehensive hospitalization databases from three states in the United States (US) to
estimate variations in RSV-attributable incidence of respiratory hospitalizations. Our results can
be used to improve RSV surveillance and to inform the potential impacts of different strategies
to prevent RSV infections.

87 Materials and Methods

88 Overview

We used hierarchical Bayesian regression models to estimate the incidence of respiratory
hospitalizations attributable to RSV infections in different age and SES groups. The model
incorporated monthly data on the number of hospitalizations recorded as due to RSV infections
(based on ICD-9-CM) while adjusting for influenza infections, seasonality and underlying
temporal trends. The goal of these analyses was to link variations in the number of
hospitalizations recorded as due to RSV infections with variations in the number of all-cause
respiratory hospitalizations ¹⁵⁻¹⁸.

96 Data sources

Data consisting of individual-level hospital discharges from the states of New York, New Jersey,
and Washington from July 2005 to June 2014 were obtained from the State Inpatient Databases
of the Healthcare Cost and Utilization Project, maintained by the Agency for Healthcare
Research and Quality (purchased through the HCUP Central Distributor) ¹⁹. Variables included
age at admission, ZIP code of residence, the recorded ICD-9-CM-diagnoses (multiple fields),

102	and the month and the year of hospital admission. The outcome in the regression was the number
103	of hospital discharges for respiratory causes by age, month, and SES classification of ZIP code
104	of residence based on median household income at the ZIP-code level. Respiratory
105	hospitalizations were defined as an ICD-9-CM code in the range 460-519 in any of the diagnosis
106	fields (including hospitalizations with diagnoses of pneumonia, bronchitis, and chronic lower
107	respiratory disease (CLRD), etc.). We analyzed hospitalizations in 9 age categories (<1, 1, 2-4,
108	5-9, 10-19, 20-44, 45-64, 65-84, 85+ years).

American Community Survey. Our analyses were based on the median household income for 2006-2011. We grouped the ZIP codes into three distinctive SES groups based on the tertile of income. ZIP codes were assigned to the same SES group for the entire period. Population estimates for each ZIP code and age group were obtained from the US Bureau of the Census for the year 2010²⁰.

Median household income at the ZIP-code level was obtained from the US Census Bureau's

109

The indicator of RSV infections in all age groups was defined as the monthly RSV-specific hospitalizations count (ICD-9-CM code: 079.6, 466.11, 480.1) among children under two years of age in the same SES group. We used RSV infections among children under two years of age as the marker for RSV infections because previous research has shown detection of RSV in children is more accurate than detection in adults ^{21 22}. Similarly, to form a more reliable indicator of influenza infections, we aggregated the influenza-specific hospitalizations count (ICD-9-CM code: 487) across age groups in the same SES group.

122 Time series of monthly count were created for each income level and age group based on the

- 123 date of hospital admission for either RSV infections or influenza infections and age
- 124 category. Data cleaning was performed with SAS software, version 9.2 (SAS Institute, Cary,
- 125 North Carolina). Statistical analyses were performed in R v4.0.2.

126 *Statistical model*

We estimated the age- and SES-specific incidence of respiratory hospitalizations attributable to 127 128 RSV using hierarchical Bayesian regression models. The model had a negative binomial 129 likelihood and identity link. The hierarchical structure provides advantages compared with fitting these models individually by group. The model pools information across all groups leading to a 130 131 reduction in uncertainty during parameter estimation while still allowing for differences between groups ²³. The identity link ensures that each covariate has an additive, rather than a 132 multiplicative, effect on the outcomes of interest ^{24 25}. Monthly and yearly dummy variables were 133 134 used to adjust for seasonality and temporal trends, respectively. Our model used seasonal dummy 135 variables instead of polynomial time trends or sinusoidal curves because the seasonal dummy 136 variable resulted in significantly improved model fit as measured by deviance information criterion (DIC) (Table S1)^{17 18 26}. Details on the model structure can be found in the 137 supplementary document with code available via GitHub 138 (https://github.com/Weinbergerlab/RSVhospitalizations_USA/blob/main/RSV_burden.Rmd). 139 After we fitted the model, the estimated "true" number of hospitalizations attributable to RSV 140 141 infections for each time point and stratum was estimated by multiplying posterior samples of the

age-specific scaling factor by the count of monthly hospitalizations that were recorded as due to

143 RSV infections among children under 2 years of age in the same SES group. The average annual 144 incidence of hospitalizations attributable to RSV infections was estimated by dividing the sum of the group-specific estimated number of hospitalizations attributable to RSV infections over nine 145 146 epidemiologic years by the age- and site-specific population. The recording ratios were calculated by dividing the number of recorded ICD-9-CM diagnoses for RSV in each age and 147 148 SES group by the modeled estimates in the same group. The attributable percent of RSV was 149 calculated by dividing the sum of the estimated number of respiratory hospitalizations 150 attributable to RSV infections by the sum of the model-predicted number of all-cause respiratory 151 hospitalizations in each age and SES group over the entire study period. (Note that model-152 predicted number of all-cause respiratory hospitalizations and recorded number of all-cause respiratory hospitalizations in each group were almost identical; The model captured 99.98% of 153 154 the variability in the recorded respiratory hospitalizations in each group.) For each measure, we 155 obtained and summarized samples from the posterior distributions of interest. The incidence was 156 rounded to two significant figures. The recording ratios and attributable percent were rounded to 157 the nearest whole number.

158 Results

159 Recorded hospitalizations

160 From July 2005 through June 2014, there were a total of 9,418,390 hospitalizations for

161 respiratory illnesses that contained detailed age and ZIP code information across the three states.

Age or ZIP code were missing for 0.1% of the records in the database, and these records were

163 excluded. There were 66,679 hospitalizations recorded as being due to RSV infections among

164 children under two years of age during the study period. State-specific information can be found165 in the supplementary document (Table S1).

166 Estimates of RSV-Associated Respiratory Hospitalizations

167 The highest estimated incidence of hospitalizations attributable to RSV infections was found in

168 infants <1 year of age (2800 per 100,000 people, 95% CrI [2600, 2900]), followed by children 1-

169 2 years of age (930 per 100,000 people, 95% CrI [830, 1000]) and by adults \geq 85 years of age

170 (970 per 100,000 people, 95% CrI [680, 1300]) (**Figure 1**). The estimated hospitalization

incidence for RSV infections among children in the ZIP codes from the lowest tertile for SES

172 was almost double that of children in the highest SES ZIP codes (Figure 1). Analyzing the data

173 from each state separately yielded similar results (see Figure S1-S3).

174 Gap between recorded and estimated RSV hospitalizations

The estimated proportion of hospitalizations caused by RSV that were recorded as being due to RSV was similar between SES groups and decreased with age (Figure 2). For example, in the highest SES group, 72% (95% CrI: 69%-76%) of estimated RSV hospitalizations among infants under 1 year of age were recorded as being caused by RSV, whereas only 3% (95% CrI: 2%-5%) of hospitalizations estimated to be due to RSV among adults \geq 85 years of age were recorded as due to RSV.

181 While most of the estimated hospitalizations attributable to RSV infections among adults ≥ 65 182 years of age were not recorded as being due to RSV, the rate of recording increased over time 183 (Figure 3). The estimated recording ratio was 1% (95% CrI: 1%-1%) in January (peak time of

184 RSV epidemics) during the 2005-2006 RSV season and increased to 12% (95% CrI: 9%-18%) in
185 January during the 2013-2014 RSV season.

186 Percent of respiratory hospitalizations attributable to RSV

Infections due to RSV were estimated to contribute to a large proportion of hospitalizations for
respiratory illnesses in young children (Figure 4). On average, 45% (95% CrI: 42%-47%) of such
hospitalizations were attributable to RSV infection in infants <1 year of age. This proportion was
smaller in older age groups (Table 1). For example, in adults 20-44 years of age, only 1% (95%
CrI: 0%-2%) of hospitalizations for respiratory infections were attributable to RSV infection.
The attributable percent was similar across SES levels.

193 **Discussion**

Understanding the incidence of hospitalizations caused by RSV can help to anticipate the 194 195 potential impacts of upcoming RSV vaccine programs in different sub-populations. In addition, information about the differences in recording ratios between subpopulations may help increase 196 197 awareness of providers about testing RSV in older adults and may lead to an improvement of 198 RSV surveillance. We estimated a considerable burden of disease in young children (<5 years of 199 age) and in the elderly (>65 years of age). The estimated incidence of hospitalizations due to 200 RSV was notably higher among patients from low SES ZIP codes. RSV was less likely to be 201 diagnosed in older adults. The percentage of hospitalizations for respiratory illnesses attributable to RSV was highest in infants and lowest among adults 20-64 years of age. With several 202 vaccines and monoclonal antibodies against RSV under active development, these estimates can 203 204 help to guide estimates of the impact of these interventions in different populations.

205 Our age-based estimates for the incidence and attributable percent of hospitalizations due to RSV infections are consistent with previous studies ^{18 27 28}. The statistical models we used in our 206 analysis are an extension of the commonly employed time series models that estimate rates of 207 respiratory virus-associated hospitalization^{15 29}. By modifying the model structure, our study 208 provides new insights into the variation in RSV-associated respiratory hospitalizations by SES 209 groups. Our estimates of the incidence of hospitalizations attributable to RSV infections among 210 211 infants <1 year of age are lower than the average incidences in published estimates in the more distant past, but comparable to the averages in recent years ^{18 27}. 212

Our estimates suggest that the incidence of hospitalizations caused by RSV has been under-213 214 recorded in the older adults. The substantial estimated incidence of hospitalizations attributable 215 RSV among those aged 65 and older agrees with earlier observations in a cohort study and time-216 series study, both of which showed that the incidence of hospitalizations attributable RSV is heavily skewed toward the older adults ^{30 27}. This age group should be considered as a potential 217 218 target population for RSV vaccines due to the potential high case-fatality rate after RSV infection ^{30 31}. The number of hospitalizations recorded as being caused by RSV increased over 219 220 the study period in the patients 65 years of age and older. This trend may reflect changes in 221 testing practices among older adults over time. To understand the actual incidence of hospitalizations attributable RSV in the elderly, more frequent testing for RSV infections is 222 needed. 223

Our results indicate that children in low-SES communities suffer from a particularly high incidence of RSV-associated hospitalizations. There are a number of potential causes for this disparity, including factors that might influence risk of viral infection, such as family size and

the number of contacts; exposure to tobacco smoke and other pollutants; high prevalence of underlying respiratory diseases like asthma and chronic lung disease from prematurity; and duration of breastfeeding ^{32 33}. Additionally, decisions to for admit patients could be influenced by the family's SES and may vary based on factors such as the co-morbid illnesses of the patients, the reliability of follow-up, and the practices of individual clinicians.

Our results suggest that about 45% of hospitalizations for respiratory illnesses in infants <1 year old are attributable to RSV infections (approximately 20 of 1000 infants/year). Monoclonal antibodies against RSV with an extended half-life ³⁴, as well as vaccination of mothers and direct vaccination of infants using live-attenuated vaccines, might help to reduce the incidence of RSV infections ³¹.

There are several caveats to our results. First, we used hospitalizations due to RSV infections 237 238 among children <2 years of age as a proxy for the timing of RSV infections in the entire 239 population. However, there may be differences in the timing of infections among the various age 240 groups. In our preliminary analyses, we tested different time lags between the various age groups, 241 but it did not improve our model fit. Since our model used monthly inpatient data, minor 242 differences in timing between age groups were less likely to be a factor. Second, the cocirculation of other respiratory viruses may confound our estimates. We may overestimate 243 244 hospitalizations attributable to RSV by not including infections due to respiratory viruses other 245 than influenza and RSV as covariates. However, previous studies indicated that most other respiratory viruses do not have the same timing as epidemics of RSV infections ³⁵⁻³⁷. Therefore, 246 247 the cocirculation of other respiratory viruses should have a relatively small impact on our estimates of RSV-attributable hospitalizations. Third, the estimates of recording ratios rely on the 248

- validity of estimates of the incidence of RSV-attributable hospitalizations. Since there is no gold
- standard of estimates of RSV-attributable hospitalizations, it is hard to validate our estimates.
- 251 Still, our age-based estimates of recording ratios are similar to those in a previous study
- conducted by the Centers for Disease Control and Prevention 27 .
- 253 In conclusion, children in families residing in low-SES areas had the highest incidence of RSV-
- associated hospitalizations for respiratory illnesses. The incidence of hospitalizations for RSV
- 255 infections in the older adults is greatly under-recorded. More comprehensive testing for RSV
- among older adults might help to better define this problem. Vaccines against RSV might
- 257 provide substantial benefit to young children and to the older adults.

258 **Conflict of Interest**

- 259 VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input
- 260 Engagements on respiratory syncytial virus. DMW has received consulting fees from Pfizer,
- 261 Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is Principal
- 262 Investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. All
- 263 other authors report no relevant conflicts.

264

265 **Funding**

266 Research reported in manuscript was fully supported by the National Institute of Allergy and

267 Infectious Diseases (MIDAS Program) of the National Institutes of Health under award number

268 R01AI137093. The content is solely the responsibility of the authors and does not necessarily

represent the official views of the National Institutes of Health.

270

271 Author contributions

ZZ implemented the study, analyzed the data and drafted the article. JLW designed the study's analytic strategy and helped prepare the Methods sections of the text. EDS helped revise the study design and manuscript for important intellectual content. VEP conceptualized the study and consulted on the analyses and revisions of the manuscript. DMW conceptualized and designed the study, and reviewed and revised the manuscript. All authors have seen and approved the final draft of the manuscript.

278

279 Acknowledgments

- 280 The authors thank Dr. Louis Bont for constructive discussion that help the authors improve the
- 281 manuscript.

283 **References:**

- Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. The New England journal of medicine 2009;**360**(6):588-98.
- 2. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute
 lower respiratory infections due to respiratory syncytial virus in young children in 2015: a
 systematic review and modelling study. Lancet 2017;390(10098):946-58.
- 289 3. PATH. RSV Vaccine and mAb Snapshot. Secondary RSV Vaccine and mAb Snapshot April 2021.
 290 <u>https://path.org/resources/rsv-vaccine-and-mab-snapshot/</u>.
- 4. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. The New England journal of
 medicine 2020;383(7):698.
- 293 5. Zheng Z, Pitzer VE, Warren JL, et al. Community factors associated with local RSV epidemic patterns: a
 294 spatiotemporal modeling study. medRxiv 2020:2020.07.06.20144345.
- 6. Noveroske DB, Warren JL, Pitzer VE, et al. Local variations in the timing of RSV epidemics. BMC
 infectious diseases 2016;**16**(1):674.
- 297 7. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower
 298 respiratory tract disease. The Journal of pediatrics 2003;**143**(5 Suppl):S118-26.
- 8. Homaira N, Mallitt KA, Oei JL, et al. Risk factors associated with RSV hospitalisation in the first 2 years
 of life, among different subgroups of children in NSW: a whole-of-population-based cohort
 study. BMJ open 2016;6(6):e011398.
- 9. Holmen JE, Kim L, Cikesh B, et al. Relationship between neighborhood census-tract level
 socioeconomic status and respiratory syncytial virus-associated hospitalizations in U.S. adults,
 2015-2017. BMC infectious diseases 2021;**21**(1):293.
- 10. Lewis KM, De Stavola B, Hardelid P. Geospatial and seasonal variation of bronchiolitis in England: a
 cohort study using hospital episode statistics. Thorax 2020;**75**(3):262-68.
- 307 11. Green CA, Yeates D, Goldacre A, et al. Admission to hospital for bronchiolitis in England: trends over
 308 five decades, geographical variation and association with perinatal characteristics and
 309 subsequent asthma. Archives of disease in childhood 2016;101(2):140-6.
- 12. Cheung CR, Smith H, Thurland K, et al. Population variation in admission rates and duration of
 inpatient stay for bronchiolitis in England. Archives of disease in childhood 2013;98(1):57-9.
- 13. Lee N, Walsh EE, Sander I, et al. Delayed Diagnosis of Respiratory Syncytial Virus Infections in
 Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the
 United States. The Journal of infectious diseases 2019;220(6):969-79.
- 14. Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clinical infectious
 diseases : an official publication of the Infectious Diseases Society of America 2010;50(5):747-51.
- 15. Taylor S, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus
 infection in children in the UK. BMJ open 2016;6(6):e009337.
- 31916. Simonsen L, Blackwelder WC, Reichert TA, et al. Estimating deaths due to influenza and respiratory320syncytial virus. JAMA 2003;289(19):2499-500; author reply 500-2.
- 17. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations Associated With Influenza and Respiratory
 Syncytial Virus in the United States, 1993-2008. Clinical Infectious Diseases 2012;54(10):1427-36.
- 18. Goldstein E, Greene SK, Olson DR, et al. Estimating the hospitalization burden associated with
 influenza and respiratory syncytial virus in New York City, 2003-2011. Influenza and other
 respiratory viruses 2015;9(5):225-33.
- 19. Healthcare Cost and Utilization Project State Inpatient Databases. Agency for Healthcare Research
 and Quality. Secondary Healthcare Cost and Utilization Project State Inpatient Databases.
- 328 Agency for Healthcare Research and Quality 2014. <u>http://www.hcup-</u>
- 329 <u>us.ahrq.gov/sidoverview.jsp</u>.

330	20. American Community Survey 1-Year Data (2005-2019). United States Census Bureau. Secondary
331	American Community Survey 1-Year Data (2005-2019). United States Census Bureau.
332	https://www.census.gov/data/developers/data-sets/acs-1year.2010.html.
333	21. Casiano-Colón AE, Hulbert BB, Mayer TK, et al. Lack of sensitivity of rapid antigen tests for the
334	diagnosis of respiratory syncytial virus infection in adults. Journal of Clinical Virology
335	2003; 28 (2):169-74.
336	22. Allen KE, Chommanard C, Haynes AK, et al. Respiratory syncytial virus testing capabilities and
337	practices among National Respiratory and Enteric Virus Surveillance System laboratories, United
338	States, 2016. Journal of clinical virology : the official publication of the Pan American Society for
339	Clinical Virology 2018; 107 :48-51.
340	23. Bolker BM, Brooks ME, Clark CJ, et al. Generalized linear mixed models: a practical guide for ecology
341	and evolution. Trends Ecol Evol 2009; 24 (3):127-35.
342	24. Gay NJ, Andrews NJ, Trotter CL, et al. Estimating deaths due to influenza and respiratory syncytial
343	virus. JAMA 2003; 289 (19):2499; author reply 500-2.
344	25. Goldstein E, Viboud C, Charu V, et al. Improving the estimation of influenza-related mortality over a
345	seasonal baseline. Epidemiology 2012; 23 (6):829-38.
346	26. Widmer K, Zhu Y, Williams JV, et al. Rates of hospitalizations for respiratory syncytial virus, human
347	metapneumovirus, and influenza virus in older adults. The Journal of infectious diseases
348	2012; 206 (1):56-62.
349	27. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory
350	syncytial virus in the United States, 1993-2008. Clinical infectious diseases : an official
351	publication of the Infectious Diseases Society of America 2012; 54 (10):1427-36.
352	28. Cassell K, Gacek P, Rabatsky-Ehr T, et al. Estimating the True Burden of Legionnaires' Disease.
353	American journal of epidemiology 2019; 188 (9):1686-94.
354 255	29. Fleming DIVI, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of Respiratory Syncytial
355	virus infection in adults and the eldeny in the United Kingdom. Bivic infectious diseases
350	ZUID; ID : 443. 20. Lee N. Lui C.C. Weng KT, et al. Lligh merhidity and mortality in adulta begaitalized for recairatory.
357 250	30. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory
220 220	Syncycial virus infections. Clinical infectious diseases : an official publication of the infectious
222	21 DATH PSV Vaccine and mAb Spanshot. Secondary PSV Vaccine and mAb Spanshot
261	bttps://path.org/recourses/recurses/r
262	22 Li P. Darling N. Maurice E. et al. Proactfooding rates in the United States by characteristics of the
362	splid mother or family: the 2002 National Immunization Survey. Pediatrics 2005: 115 (1):e31.7
364	33 Prevention CfDCa. Cigarette Smoking and Tobacco Llse Among People of Low Socioeconomic Status
365	Secondary Cigarette Smoking and Tobacco Use Among People of Low Socioeconomic Status.
366	November 25, 2019, https://www.cdc.gov/tobacco/disparities/low-ses/index.htm
367	34 AstraZeneca Nirsevimah MELODY Phase III trial met primary endpoint of reducing RSV lower
368	respiratory tract infections in healthy infants. Secondary Nirsevimab MELODY Phase III trial met
369	primary endpoint of reducing RSV lower respiratory tract infections in healthy infants
370	35. Byington CL, Ampofo K, Stockmann C, et al. Community Surveillance of Respiratory Viruses Among
371	Families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE)
372	Study. Clinical Infectious Diseases 2015: 61 (8):1217-24.
373	36. Price OH, Sullivan SG, Sutterby C, et al. Using routine testing data to understand circulation patterns
374	of influenza A, respiratory syncytial virus and other respiratory viruses in Victoria. Australia.
375	Epidemiology and infection 2019; 147 :e221.

- 376 37. Landes MB, Neil RB, McCool SS, et al. The frequency and seasonality of influenza and other
- 377 respiratory viruses in Tennessee: two influenza seasons of surveillance data, 2010-2012.
- 378 Influenza and other respiratory viruses 2013;7(6):1122-7.

380 Tables

	Low SES		Medium SES		High SES	
Age (in years)	Mean	95% CrI	Mean	95% CrI	Mean	95% CrI
<1	44%	(42%, 46%)	46%	(44%, 48%)	46%	(44%, 48%)
1	27%	(24%, 29%)	29%	(25%, 31%)	27%	(24%, 29%)
2-4	18%	(16%, 20%)	21%	(18%, 23%)	18%	(16%, 20%)
5-9	9%	(7%, 11%)	11%	(8%, 13%)	9%	(7%, 11%)
10-19	3%	(2%, 4%)	4%	(2%, 5%)	3%	(2%, 4%)
20-44	1%	(0%, 2%)	1%	(0%, 2%)	1%	(0%, 2%)
45-64	1%	(0%, 2%)	1%	(0%, 2%)	1%	(0%, 2%)
65-84	2%	(1%, 3%)	2%	(1%, 3%)	1%	(1%, 2%)
85+	4%	(3%, 6%)	4%	(2%, 5%)	2%	(1%, 3%)

Table 1. Estimated Percentage of Respiratory Hospitalizations Attributable to RSV infections, by SES and Age Group, 2005–2014

384 Figure Legends

Figure 1. Estimated RSV-attributable respiratory hospitalization rates by age and SES

- **group, July 2005 June 2014.** The color texts show the mean estimates of RSV-attributable
- respiratory hospitalization rates in each age and SES group. The error bars indicate the 95%
- 388 credible intervals of the estimated RSV-attributable respiratory hospitalization rates. Color blue,
- yellow, and orange correspond to the estimates in populations from low, medium, and high SES
- 390 ZIP codes.

391 Figure 2. Ratio of the number of hospitalizations recorded as being due to RSV and the

number of estimated RSV hospitalizations, by age and SES group, July 2005 - June 2014.

- 393 The size of the circles represents the estimated proportion of hospitalizations caused by RSV that
- 394 were recorded. The texts show the mean estimates of the recording ratio in each age and SES
- group. The shaded areas indicate the 95% credible intervals of the reporting ratio. Color blue,
- 396 yellow, and orange correspond to the estimates in populations from low, medium, and high SES
- 397 ZIP codes.

Figure 3. Respiratory hospitalizations among older adults, July 2005 - June 2014. The blue

- area in the left panel shows the total respiratory hospitalization rate among adults aged 65 and
- 400 above; the yellow area shows the estimated RSV-associated respiratory hospitalizations in the
- same age group and the red area shows the hospitalizations recorded as RSV. The right panel
- 202 zooms in to show the increasing trend of recording RSV diagnoses.

403 **Figure 4. Respiratory hospitalizations in infants <1 year of age, July 2005 - June 2014.** The

- 404 blue area shows the total respiratory hospitalization rate in infants <1 year of age; the yellow area
- shows the estimated RSV-associated respiratory hospitalizations in the same age group and the
- 406 red area shows the hospitalizations recorded as being due to RSV.



300 ₂₅₀ 180 •	83 65 41	
2-4	5-9	10-19
		Age group











Total Estimated RSV **Recorded RSV**





2006





2012

Respiratory Hospitalizations



Total Estimated RSV Recorded RSV